Modakafusp alfa is targeted to CD38, not IFNAR2. After binding CD38+ cells, its IFN-alpha moiety engages IFNAR1/IFNAR2 to trigger type I interferon signaling, inducing antiproliferative/apoptotic effects in those CD38-bound cells; IFNAR2 expression alone is not sufficient for targeted killing.